Experts red-flag cancer drug price cuts as patented therapies see zero relief, markups exceed benchmark
Experts said there should be comprehensive, cost-based price controls covering all oncology therapies, permanent statutory margin caps across distribution channels and full scrutiny of company assistance programmes.
Mint asks for a subscription to read the full story. If you have one, sign in on their site.
0 comments